What is it about?
The possible reemergence of smallpox through bioterrorism requires the preparation of adequate stockpiles of vaccine. Dryvax, the only US-licensed vaccinia virus smallpox vaccine, has an unacceptable safety profile in the pre-event setting. LC16m8 is a Japanese-licensed attenuated vaccinia virus strain that has been safely used in over 50,000 persons. Until now, efficacy of this vaccine was unproven.
Featured Image
Why is it important?
Using two animal models, we show that LC16m8 and Dryvax elicit comparable humoral immune responses after a single vaccination and equivalently protect against lethal poxvirus disease. Thus, LC16m8 shows promise as a safe and effective smallpox vaccine with the potential for replacing Dryvax.
Read the Original
This page is a summary of: Highly attenuated smallpox vaccine protects rabbits and mice against pathogenic orthopoxvirus challenge, Vaccine, April 2006, Elsevier,
DOI: 10.1016/j.vaccine.2005.03.029.
You can read the full text:
Contributors
The following have contributed to this page
